OMIDRIA Special Ep. 2: Using OMIDRIA for Mitigating Risk in Cataract Surgery episode artwork

EPISODE · Jul 26, 2023 · 13 MIN

OMIDRIA Special Ep. 2: Using OMIDRIA for Mitigating Risk in Cataract Surgery

from Peer2Peer: The Podcast · host Rayner

In this second episode of ‘Peer2Peer: The Podcast’ focused on OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3, host Dr Arjan Hura, discusses the use of OMIDRIA with Dr. Cathleen McCabe and Dr. Neda Shamie. They highlight the challenges faced by surgeons who suffer from high workloads and how OMIDRIA can help mitigate some of the risks associated with stress in case of complications. Additionally, they explain the benefits of using OMIDRIA with high-risk patients, and the reasons why they often apply it in less complicated cases as well.   This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon's independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases. OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.   Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300031 07/23   IMPORTANT SAFETY INFORMATION  OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation. Please see the Full Prescribing Information for OMIDRIA: https://www.omidriahcp.com/documents/8/OMIDRIA-Prescribing-Information.pdf  

Episode metadata supplied by the publisher feed · Published Jul 26, 2023

Embed this episode

Ready to play

OMIDRIA Special Ep. 2: Using OMIDRIA for Mitigating Risk in Cataract Surgery

0:00 13:29

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Peer2Peer: The Podcast?

This episode is 13 minutes long.

When was this Peer2Peer: The Podcast episode published?

This episode was published on July 26, 2023.

Can I download this Peer2Peer: The Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!